AZNAstraZenecaSigning up patients
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 582 (planned)
- Started
- Apr 29, 2024
- Main results expected
- Mar 21, 2028
- Fully finished
- Aug 29, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.
Measured over: It is anticipated that it will be performed approximately 3 years after the first participant is randomised.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06350097 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC